Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Clavis Pharma was originally established as ConPharma in August 2001 to develop new and improved pharmaceuticals
utilising its proprietary Lipid Vector Technology (LVT). LVT involves the chemical binding of specific fatty acids to
pharmaceutical agents, thereby creating new chemical entities with improved biological properties such as increased
cellular uptake, reduced toxicity and slow release of the active compound. The fatty acids used by Clavis Pharma are
natural constituents of human nutrition. The company has demonstrated that the LVT has the potential to improve drug
performance and to open new indications for existing pharmaceuticals in a variety of therapeutic areas such as cancer
and viral diseases.